ΔF508 heterozygosity in cystic fibrosis and susceptibility to asthma

Lancet

Volumn 351, Issue 9120, 1998, Pages 1911-1913

  Dahl, Morten ^a   Tybjaerg Hansen A ^a,b   Lange, Peter ^b   Nordestgaard, Børge G ^a,b,c  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b BISPEBJERG HOSPITAL   (Denmark)

^c GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CYSTIC FIBROSIS; DENMARK; DISEASE PREDISPOSITION; FEMALE; FORCED EXPIRATORY VOLUME; GENOTYPE; HETEROZYGOSITY; HUMAN; LUNG DISEASE; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECESSIVE INHERITANCE; RISK; SMOKING; SPIROMETRY; VITAL CAPACITY; CROSS-SECTIONAL STUDY; GENETICS; HETEROZYGOTE; HETEROZYGOTE DETECTION; MIDDLE AGED;

CFTR PROTEIN, HUMAN; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ASTHMA; CROSS-SECTIONAL STUDIES; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DENMARK; DISEASE SUSCEPTIBILITY; FEMALE; HETEROZYGOTE; HETEROZYGOTE DETECTION; HUMANS; MALE; MIDDLE AGED; SPIROMETRY;

EID: 0032572187     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)11419-2     Document Type: Article

References (25)

1. 1 Woolcock A. Asthma. In: Nadel J, Murray J, eds. Textbook of respiratory medicine, 2nd edn. Philadelphia: WB Saunders, 1994: 1288-330.
2. 2 Murray CJL, Lopez AD. Mortality by cause for eight regions of the world: global burden of disease study. Lancet 1997; 349: 1269-76.
3. 3 Welsh M, Tsui L, Boat T, Beaudet A. Cystic fibrosis. In: Scriver C, Beaudet A, Sly W, Valle D, eds. The metabolic and molecular bases of inherited disease, 7th edn. New York: McGraw-Hill, 1995: 3799-876.
4. 4 Davis P, Drumm M, Konstan M. Cystic fibrosis. Am J Respir Crit Care Med 1996; 154: 1229-56.
5. 5 Schwarte M, Brandt N, Koch C, Lanng S, Schiøte P. Genetic analysis of cystic fibrosis in Denmark: implications for genetic counselling, carrier diagnosis and prenatal diagnosis. Acta Paediatr 1992; 81: 522-26.
6. 6 Wittrup HH, Tybjærg-Hansen A, Abildgaard S, Steffensen R, Schnohr, P, Nordestgaard BG. A common substitution (Asn291Ser) in lipoprotein lipase is associated with increased risk of ischemic heart disease. J Clin Invest 1997; 99: 1606-13.
7. -455→A) in the β-fibrinogen promoter is an independent predictor of plasma fibrinogen, but not of ischemic heart disease. J Clin Invest 1997; 99: 3034-39.
8. 8 Appleyard M, Hansen A, Schnohr P, Jensen G, Nyboe J. The Copenhagen City Heart Study: a book of tables with data from the first examination (1976-78) and a five year follow-up (1981-83). Scand J Soc Med 1989; 170 (suppl 41): 1-160.
9. 9 Lange P, Nyboe J, Jensen G, Schnohr P, Appleyard M. Ventilatory function impairment and risk of cardiovascular death and of fatal or non-fatal myocardial infarction. Eur Respir J 1991; 4: 1080-87.
10. 10 Gold WM. Pulmonary function testing. In: Nadel J, Murray J, eds. Textbook of respiratory medicine, 2nd edn. Philadelphia: WB Saunders, 1994: 870-71.
11. 11 Wood J, Fishman A, Reemtsma K, Barker H, di Sant' Agnese P. A comparison of sweat chlorides and intestinal fat absorption in chronic obstructive pulmonary emphysema and fibrocystic disease of the pancreas. N Engl J Med 1959; 260: 951-57.
12. 12 Orzalesi M, Kohner D, Cook C, Shwachman H. Anamnesis, sweat electrolyte and pulmonary function studies in parents of patients with cystic fibrosis of the pancreas. Acta Paediatr Scand 1963; 52: 267-76.
13. 13 Batten J, Muir D, Simon G, Carter C. The prevalence of respiratory disease in heterozygotes for the gene for fibrocystic disease of the pancreas. Lancet 1963; i: 1348-50.
14. 14 Hallet W, Knudson A, Massey F. Absence of detrimental effect of the carrier state for the cystic fibrosis gene. Am Rev Respir Dis 1965; 90: 714-24.
15. 15 Byard P, Davis P. Pulmonary function in obligate heterozygotes for cystic fibrosis. Am Rev Respir Dis 1988; 138: 312-16.
16. 16 Sandford AJ, Weir TD, Paré PD. Genetic risk factors for chronic obstructive pulmonary disease. Eur Respir J 1997; 10: 1380-91.
17. 17 Mitchell I, Corey M, Woenne R, Krastins I, Levison H. Bronchial hyperreactivity in cystic fibrosis and asthma. J Pediatr 1978; 93: 744-48.
18. 18 Leupold W, Dietesch H. Bronchial reactivity in children with cystic fibrosis and other recurrent or chronic bronchopulmonary diseases. Monogr Paediatr 1979; 10: 119-22.
19. 19 Counahan R, Mearns M. Prevalence of atopy and exercise-induced bronchial lability in relatives of patients with cystic fibrosis. Arch Dis Child 1975; 50: 477-81.
20. 20 Davis P. Autonomic and airway reactivity in obligate heterozygotes for cystic fibrosis. Am Rev Respir Dis 1984; 129: 911-14.
21. 21 Davis P, Vargo K. Pulmonary abnormalities in obligate heterozygotes for cystic fibrosis. Thorax 1987; 42: 120-25.
22. 22 Davis P, Byard P. Heterozygotes for cystic fibrosis: models for study of airway and autonomic reactivity. J Appl Physiol 1989; 66: 2124-28.
23. 23 Schroeder SA, Gaughan DM, Swift M. Protection against bronchial asthma by CFTR ΔF508 mutation: a heterozygote advantage in cystic fibrosis. Nat Med 1995; 1: 703-05.
24. 24 Mennie M, Gilfillan A, Brock DJH, Liston WA. Heterozygotes for the ΔF508 cystic fibrosis allele are not protected against bronchial asthma. Nat Med 1995; 1: 978-79.
25. 25 Khoury M, Beaty T, Cohen B. In: Fundamentals of genetic epidemiology. New York: Oxford University Press, 1993: 77-79, 107-108.